Aktieanalyser från populära analyshus

19 May 12:02

Initiator Pharma: Indication expansion and SEK56.2m rights issue - Redeye

XP Chemistries: Positivt EFSA-utlåtande, en game changer - Mangold Insight Analys

I april 2025 lämnade EFSA (Europeiska myndigheten för livsmedelssäkerhet) ett positivt vetenskaplig...

Angler Gaming: Rapportkommentar Q1'25 - Kalqyl

Angler Gaming

19 May 10:59

Analyst Group kommenterar Biofrigas och pågående företrädesemission

Biofrigas Sweden AB (publ) (”Biofrigas” eller ”Bolaget”) är verksamma på den växande marknaden för f...

Biofrigas

19 May 10:57

Ogunsen: H2 recovery still on the cards - ABG

Ogunsen

19 May 10:56

Projektengagemang: Uncertainty remains - ABG

No real progress in Q1 Market to turn positive in '25e, according to report Turnaround delayed, '25e...

Projektengagemang

19 May 10:42

Energy Save: Cool Q2 ahead, but H2'25e set to heat up - ABG

ES Energy Save

19 May 10:05

STENOCARE: Time to Capitalize on STENOCARE 3.0 - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products app...

Biovica: Signs its fourth tier-1 oncology Master Service Agreement based on DiviTum - Redeye

Angler Gaming kv1 2025: Starka marginaler men utebliven tillväxt - Carlsquare

Angler Gaming plc (”Angler” eller ”Bolaget”) levererade en kv1 2025-rapport under vår förväntan avse...

Angler Gaming

19 May 09:45

Analyst Group kommenterar Luxbrights nya order om 0,3 MSEK från VJ X-Ray

Ascelia Pharma update: Funded for near-term triggers ahead - Redeye

After the warrant contribution, Ascelia Pharma is well funded for 2025 with some SEK 80m net cash, w...

Ascelia Pharma

19 May 08:38

Ferronordic: Net debt down sequentially, but still high - ABG

CLS Q1: A solid quarter largely in line with our expectations - Redeye

Redeye provides an update following CLS’s Q1 2025 report.

Clinical Laserthermia

Analys | Redeye

19 May 07:17

Lytix Biopharma Q1 2025: Progress in NeoLIPA but Financial Weakness for Verrica - Redeye

Safello: Charts course through crypto volatility - Redeye

Redeye states Safello's report came in on the weaker side in a quarter with a challenging backdrop.

Paxman Q1: Softer quarter than expected, but CIPN adds long-term value - Redeye

Dala Energi: Steady she goes - Redeye

Redeye reiterates its fair value range following Dala Energi’s Q1 report that was published last Fri...

Dala Energi

16 May 14:46

Ework Group: Automotive drag and rebalancing impact - ABG

eWork

16 May 14:46

BTS Group: Putting faith in an improved 2025 - ABG

Q1 miss, 2025-27e adj. EBITA cut 4-5% FY guidance kept, we estimate 7% EBITA growth in 2025e Share a...

BTS Group

16 May 11:45

Analyst Group Comments on HydrogenPro’s Q1-report

HydrogenPro

16 May 10:07

Energy Save: Sales growth but weak FCF on NWC - ABG

Sales SEK 54m (ABGSCe 55m), EBIT -4m (ABGSCe -7m) Market conditions remain soft, anticipates weaker ...

Elicera Therapeutics: All eyes on upcoming data - Redeye

Dala Energi Q1 2025: No real surprises - Redeye

Redeye briefly comments on Dala Energi’s Q1 report, which presented no real surprises.

Dala Energi

Analys | Analysguiden

16 May 10:06

VNV GLOBAL: Voi fortsätter att växa med förbättrad lönsamhet - Analysguiden

VNV Global

Analys | Analysguiden

16 May 10:05

Angler Gaming: Ny affärsmodell för B2B stärker lönsamheten - Analysguiden

Omsättningen sjönk till 8,2 (10,2) meur, varav PremierGaming stod för 6,7%.

Safello Q1 2025: Challenging market backdrop - Redeye

Ascelia Pharma Q1: FDA submission on track for mid-year, most likely early August - Redeye

The FDA submission is progressing toward the finish line, as illustrated by the more precise expecte...

Ascelia Pharma

Analys | Analysguiden